Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
80 hedge funds and large institutions have $71.2M invested in Cascadian Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 17 closing their positions.
449% more call options, than puts
Call options by funds: $593K | Put options by funds: $108K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 22
14% less funds holding
Funds holding: 93 → 80 (-13)
46% less capital invested
Capital invested by funds: $132M → $71.2M (-$60.5M)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$948K |
| 2 |
FO
FT Options
Chicago,
Illinois
|
+$918K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$433K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$371K |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$5.17M |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$1.14M |
| 3 |
NC
Nexthera Capital
New York
|
-$444K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$432K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$382K |
CASC Hedge Fund Activity: Q1 2016 in Review
80 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2016, worth a combined $71.2M — down 46% from $132M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CASC and 6 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 21 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $948K. The largest seller was Redmile Group, exiting entirely with an estimated $5.17M sold.
- 80 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q1 2016, down from 93 in Q4 2015.
- Funds reported $71.2M of Cascadian Therapeutics, Inc. stock for Q1 2016, down 46% quarter-over-quarter.
- 6 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2016 and 17 closed out, a net change of -11 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q1 2016 was Sabby Management, an estimated $948K added.
- The largest Cascadian Therapeutics, Inc. seller in Q1 2016 was Redmile Group, an estimated $5.17M sold.
Based on aggregated 13F filings for Q1 2016.